13F Holdings
中文EN

IFRX InflaRx N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1708688 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-82.3%
TTM net income YoY0.9%
TTM EPS YoY12.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-24,677.9%
Operating margin—
Net margin-155,582.1%
FCF margin—
EBITDA margin—

Returns

ROE-624.6%
ROA-69.5%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets24.7%
Debt / equity0.00x
Current ratio4.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2022*2021-12-31
Income statement
Revenue29,331165,78963,089——
Cost of revenue7.27M3.32M532,262——
Gross profit-7.24M-3.15M-469,173——
R&D expense25.72M35.36M41.02M37.53M35.70M
SG&A expense15,96341,40095,20597,413105,790
Operating income——-44.91M-32.24M-47.63M
Interest expense2,69288516,53823,30310,714
Pretax income-45.62M-46.06M-42.67M-29.48M-45.63M
Income tax12,2825,217——0
Net income-45.63M-46.06M-42.67M-29.48M-45.63M
EPS (basic)-0.68-0.78-0.78-0.67-1.10
EPS (diluted)-0.68-0.78-0.78-0.67-1.10
Weighted avg. shares (diluted)————41.63M
Balance sheet
Cash & equivalents16.02M18.38M12.77M16.27M26.25M
Short-term investments———3,42212.58M
Inventory—6.90M11.37M——
Current assets53.63M71.66M109.47M97.41M95.68M
PP&E, netmay include right-of-use assets (IFRS)289,317256,280289,577328,920274,373
Intangibles———138,905235,216
Total assets55.22M76.02M120.21M102.40M125.14M
Current liabilities12.98M14.17M16.84M13.03M18.76M
Long-term debt————0
Total debt————0
Total liabilities13.66M14.60M17.63M14.05M19.86M
Shareholders' equity7.17M7.44M7.38M7.26M105.28M
Net debt————-26.25M
Cash flow statement
Operating cash flow-35.31M-48.56M-37.81M-33.74M-39.94M
Investing cash flow3.23M52.36M-17.70M19.36M-25.95M
Financing cash flow33.32M386,44652.99M1.94M61.58M
Stock-based compensation4.44M4.07M3.41M6.04M4.33M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.